FAQs

The COPD Drug Development Summit is a dedicated, industry‑leading meeting focused on accelerating the development of next‑generation therapies for chronic obstructive pulmonary disease. It brings together experts from pharma, biotech and academia to share the latest scientific insights, clinical strategies, and technological innovations shaping the future of COPD treatment. The summit provides a platform for collaboration, problem-solving, and knowledge exchange across the full drug development lifecycle. 

This summit is designed for professionals involved in respiratory drug development, including leaders in R&D, translational science, clinical development, biomarker discovery, regulatory affairs, and drug delivery. Attendees typically include scientists, clinicians, program directors, regulatory strategists, and executives from pharmaceutical companies, biotech innovators, CROs, and academic research institutions working to advance COPD therapeutics. 

The summit will take placein Boston, on September 9th – 11th, bringing together global respiratory drug development experts in one central location.  

The agenda spans the most pressing challenges and emerging opportunities in COPD drug development, including: 

• Novel therapeutic modalities such as biologics, RNA‑based therapies, and regenerative approaches
• Advances in COPD phenotyping and endotyping
• Biomarker discovery and validation
• Innovations in clinical trial design and patient stratification
• Regulatory expectations and evolving guidance
• Translational strategies to improve efficacy and reduce attrition
• Real‑world evidence and digital tools for COPD research

The program is curated to reflect the latest scientific breakthroughs and industry priorities. 

Unlike broader respiratory meetings, the COPD Drug Development Summit is uniquely focused on therapeutic innovation and clinical advancement specifically for COPD. It brings together a highly targeted audience of drug developers and scientific leaders, enabling deeper technical discussions, more actionable insights, and stronger industry collaboration. The summit also emphasises real‑world case studies, emerging modalities, and practical strategies that directly support pipeline progression. 

We are unable to provide the full list of attendees publicly. If you are interested to find out the audience breakdown, please contact us here for a more detailed breakdown of all our current confirmed attendees.